More on Regeneron (REGN) Q2: swings to net profit of $76.7M from loss of $62.5M last year,...

|About: Regeneron Pharmaceuticals... (REGN)|By:, SA News Editor

More on Regeneron (REGN) Q2: swings to net profit of $76.7M from loss of $62.5M last year, boosted by sales of its Eylea eye treatment, which surged 57% Q/Q to $194M. Increases FY Eylea sales forecast for the 3rd time, now expecting $700M-$750M vs. $500M-$550M previously. Eylea taking market share from Roche's Lucentis and off-label Avastin. Shares +3.85%.